We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $1.06B
1-Year Est. Return 52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
Cap. Flow
+$137M
Cap. Flow %
12.89%
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$28.5M
2
MRK icon
Merck
MRK
+$25M
3
UNH icon
UnitedHealth
UNH
+$17.8M
4
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
5
CNC icon
Centene
CNC
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.1M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
VEEV icon
Veeva Systems
VEEV
+$11.2M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.99M
5
BSX icon
Boston Scientific
BSX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$1.95B
$9.86M 0.93%
141,250
+82,250
+139% +$6.02M
ALKS icon
52
Alkermes
ALKS
$6.85B
$9.71M 0.92%
185,250
+52,000
+39% +$2.03M
ABT icon
53
Abbott
ABT
$175B
$8.71M 0.82%
96,000
-16,000
-14% -$1.46M
DNTH icon
54
Dianthus Therapeutics
DNTH
$4.95B
$8.4M 0.79%
86,127
+4,500
+6% +$393K
PRCT icon
55
Procept Biorobotics
PRCT
$985M
$7.79M 0.74%
345,000
-130,000
-27% -$3.25M
GPCR icon
56
Structure Therapeutics
GPCR
$2.56B
$7.79M 0.74%
145,100
+17,000
+13% +$752K
ORKA
57
Oruka Therapeutics
ORKA
$5.59B
$7.61M 0.72%
+80,000
New +$5.33M
EHC icon
58
Encompass Health
EHC
$12.2B
$7.51M 0.71%
74,263
+18,000
+32% +$1.86M
MLTX icon
59
MoonLake Immunotherapeutics
MLTX
$1.02B
$7.49M 0.71%
384,800
+145,300
+61% +$2.63M
IOVA icon
60
Iovance Biotherapeutics
IOVA
$4.98B
$7.09M 0.67%
1,705,327
-350,000
-17% -$1.33M
BBIO icon
61
BridgeBio Pharma
BBIO
$12.8B
$6.79M 0.64%
91,100
+500
+0.6% +$35K
KURA icon
62
Kura Oncology
KURA
$957M
$6.49M 0.61%
591,500
+320,000
+118% +$3.02M
PODD icon
63
Insulet
PODD
$9.44B
$6.39M 0.6%
42,000
+28,000
+200% +$4.66M
ERAS icon
64
Erasca
ERAS
$4.98B
$6.39M 0.6%
+349,000
New +$4.99M
KRYS icon
65
Krystal Biotech
KRYS
$10.2B
$6.07M 0.57%
16,325
-350
-2% -$105K
STVN icon
66
Stevanato
STVN
$5.77B
$5.53M 0.52%
305,972
+31,296
+11% +$529K
ASTH icon
67
Astrana Health
ASTH
$1.8B
$5.52M 0.52%
+118,888
New +$4.28M
CAH icon
68
Cardinal Health
CAH
$51B
$5.35M 0.5%
22,500
-4,500
-17% -$935K
ALNY icon
69
Alnylam Pharmaceuticals
ALNY
$34.2B
$5.18M 0.49%
17,200
-17,265
-50% -$5.21M
MOH icon
70
Molina Healthcare
MOH
$9.96B
$5M 0.47%
+21,857
New +$3.96M
VKTX icon
71
Viking Therapeutics
VKTX
$4.15B
$4.99M 0.47%
128,000
-32,000
-20% -$1.03M
CI icon
72
Cigna
CI
$71.9B
$4.8M 0.45%
17,400
+9,400
+118% +$2.66M
IONS icon
73
Ionis Pharmaceuticals
IONS
$7.4B
$4.75M 0.45%
59,900
-33,000
-36% -$2.48M
AMN icon
74
AMN Healthcare
AMN
$1.34B
$4.68M 0.44%
+144,466
New +$3.73M
DNLI icon
75
Denali Therapeutics
DNLI
$3.26B
$4.6M 0.43%
179,000
-20,000
-10% -$411K
1 2
3
4 5

Similar funds

JSC
J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return
PCI
Planning Center Inc Moline, Illinois $1.06B AUM 12.82% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
BDP
Brehaut David Pascal $1.06B AUM
GX
Greylock XIV Menlo Park, California $1.06B AUM
CIC
Cutler Investment Counsel Jacksonville, Oregon $1.06B AUM 20.29% 1-Year Est. Return
RCIM
Red Cedar Investment Management Grand Rapids, Michigan $1.06B AUM 30.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
  • Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $9.99M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
  • Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.